The efficacy and safety of pharmaceutical products are intrinsically linked to the quality of their raw materials. For pharmaceutical intermediates, adherence to strict quality standards is not just a best practice; it's a regulatory imperative. D-Threo-Methylphenidate Hydrochloride (CAS 19262-68-1) serves as an excellent example of a chemical that requires rigorous quality assurance throughout its production and supply chain.

A cornerstone of quality for such compounds is their purity. A minimum assay of 99% for D-Threo-Methylphenidate Hydrochloride, as provided by manufacturers like NINGBO INNO PHARMCHEM CO.,LTD., is a critical indicator of its suitability for pharmaceutical applications. Impurities, even in trace amounts, can lead to unintended side reactions, reduced product yield, or the presence of unwanted by-products in the final drug substance, potentially impacting patient safety and regulatory approval.

When manufacturers aim to buy D-Threo-Methylphenidate Hydrochloride, they look for suppliers who provide comprehensive quality documentation, including certificates of analysis (CoA) that detail purity, physical and chemical properties, and often, adherence to specific pharmacopeial standards if applicable. The CAS number, 19262-68-1, acts as a unique identifier for this quality assurance process.

Beyond purity, factors such as consistent physical form (e.g., white to off-white solid), appropriate packaging (like the 25kg/drum standard), and reliable handling are equally important. These elements contribute to maintaining the integrity of the chemical intermediate from the point of manufacture to its use in the next stage of synthesis. By prioritizing suppliers who demonstrate a robust quality management system, pharmaceutical companies can mitigate risks and ensure the successful development and production of their medicinal products.